During the last session, Eledon Pharmaceuticals Inc (NASDAQ:ELDN)’s traded shares were 0.33 million, with the beta value of the company hitting -0.15. At the end of the trading day, the stock’s price was $3.42, reflecting an intraday loss of -0.87% or -$0.03. The 52-week high for the ELDN share is $5.54, that puts it down -61.99 from that peak though still a striking 30.41% gain since the share price plummeted to a 52-week low of $2.38. The company’s market capitalization is $204.79M, and the average intraday trading volume over the past 10 days was 1.15 million shares, and the average trade volume was 357.49K shares over the past three months.
Eledon Pharmaceuticals Inc (ELDN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ELDN has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) trade information
Eledon Pharmaceuticals Inc (ELDN) registered a -0.87% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.87% in intraday trading to $3.42, hitting a weekly high. The stock’s 5-day price performance is 11.04%, and it has moved by 14.38% in 30 days. Based on these gigs, the overall price performance for the year is -16.99%. The short interest in Eledon Pharmaceuticals Inc (NASDAQ:ELDN) is 1.33 million shares and it means that shorts have 6.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 62.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $9 respectively. As a result, ELDN is trading at a discount of -163.16% off the target high and -163.16% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 50.24%. While earnings are projected to return -9.78% in 2025, the next five years will return -14.98% per annum.
ELDN Dividends
Eledon Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Eledon Pharmaceuticals Inc (NASDAQ:ELDN)’s Major holders
Eledon Pharmaceuticals Inc insiders own 1.40% of total outstanding shares while institutional holders control 68.20%, with the float percentage being 69.17%. BVF INC/IL is the largest shareholder of the company, while 95.0 institutions own stock in it. As of 2024-06-30, the company held over 6.29 million shares (or 14.8853% of all shares), a total value of $16.61 million in shares.
The next largest institutional holding, with 2.34 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 5.5253% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.17 million.
Also, the Mutual Funds coming in first place with the largest holdings of Eledon Pharmaceuticals Inc (ELDN) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.88 shares. This amounts to just over 3.15 percent of the company’s overall shares, with a $6.44 million market value. The same data shows that the other fund manager holds slightly less at 974.99, or about 1.63% of the stock, which is worth about $3.33 million.
